Biomarker-based ovarian carcinoma typing: A histologic investigation in the ovarian tumor tissue analysis consortium

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 10, 2013, Pages 1677-1686

  Köbel, Martin ^a   Kalloger, Steve E ^c   Lee, Sandra ^a   Duggan, Maire A ^a   Kelemen, Linda E ^b   Prentice, Leah ^c   Kalli, Kimberly R ^a   Fridley, Brooke L ^e   Visscher, Daniel W ^a   Keeney, Gary L ^a   Vierkant, Robert A ^a   Cunningham, Julie M ^a   Chow, Christine ^c   Ness, Roberta B ^f   Moysich, Kirsten ^g   Edwards, Robert ^a,h,i   Modugno, Francesmary ^a,h,i   Bunker, Clareann ^j   Wozniak, Eva L ^k   Benjamin, Elizabeth ^l   Gayther, Simon A ^m   Gentry Maharaj, Aleksandra ^k   Menon, Usha ^k   Gilks, C Blake ^c   Huntsman, David G ^c   Ramus, Susan J ^m   Goode, Ellen L ^d   more..

^a Department of Pathology and Laboratory Medicine ^*  (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^g ROSWELL PARK CANCER INSTITUTE   (United States)

^h UNIVERSITY OF PITTSBURGH   (United States)

ⁱ UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

^l UNIVERSITY COLLEGE LONDON   (United Kingdom)

^m UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DICKKOPF 1 PROTEIN; HEPATOCYTE NUCLEAR FACTOR 1BETA; PROTEIN MDM2; PROTEIN P53; RETINOBLASTOMA BINDING PROTEIN 2; WT1 PROTEIN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CELL LINEAGE; COHORT ANALYSIS; COLLOID CARCINOMA; ENDOMETRIOID CARCINOMA; EXTERNAL VALIDITY; FEASIBILITY STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERNAL VALIDITY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVARY TUMOR; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84886376233     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0391     Document Type: Article

References (41)

1. Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008;5:e232.
2. Kurman RJ, Shih I-M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010;34:433-43.
3. Köbel M, Kalloger SE, Baker PM, Ewanowich CA, Arseneau J, Zherebitskiy V, et al. Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study. Am J Surg Pathol 2010;34: 984-93.
4. Köbel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD, et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol 2010;29: 203-11.
5. Crum CP, McKeon FD, Xian W. BRCA, the oviduct, and the space and time continuum of pelvic serous carcinogenesis. Int J Gynecol Cancer 2012;22 Suppl 1:S29-34.
6. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010;363:1532-43.
7. Kurman RJ, Shih I-M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-Shifting the paradigm. Hum Pathol 2011;42:918-31.
8. Zorn KK, Bonome T, Gangi L, Chandramouli GVR, Awtrey CS, Gardner GJ, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 2005;11:6422-30.
9. Köbel M, Kalloger SE, Santos JL, Huntsman DG, Gilks CB, Swenerton KD. Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. Gynecol Oncol 2010; 116:50-6.
10. Mackay HJ, Brady MF, Oza AM, Reuss A, Pujade-Lauraine E, Swart AM, et al. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer 2010;20:945-52.
11. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011;12:852-61.
12. McAlpine JN, Wiegand KC, Vang R, Ronnett BM, Adamiak A, Kobel M, et al. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer 2009;9:433.
13. Anglesio MS, Carey MS, Köbel M, Mackay H, Huntsman DGVancouver Ovarian Clear Cell Symposium Speakers. Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecol Oncol 2011;121:407-15.
14. Kelemen LE, Köbel M. Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. Lancet Oncol 2011;12:1071-80.
15. Diaz-Padilla I, Malpica AL, Minig L, Chiva LM, Gershenson DM, Gonzalez-Martin A. Ovarian low-grade serous carcinoma: a comprehensive update. Gynecol Oncol 2012;126:279-85.
16. Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 2012;13:385-94.
17. Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E, et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 2009;41:996-1000.
18. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 2010;42:874-9.
19. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25:1329-33.
20. Patel C, Harmon B, Soslow RA, Garg K, DeLair D, Hwang S, et al. Interobserver agreement in the diagnosis of ovarian carcinoma types: impact of sub-specialization. Lab Invest 2012;92:292A.
21. Gilks CB, Ionescu DN, Kalloger SE, Köbel M, Irving J, Clarke B, et al. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol 2008;39:1239-51.
22. Gilks CB, Clarke BA, Han G, Köbel M, Longacre T, McCluggage WG, et al. Letter to the editor regarding 'Roh MH, Lassin Y, Miron A et al. High-grade fimbrial-ovarian carcinomas are unified by p53, PTEN and PAX2 expression'. Mod Pathol 2011;24:1281-2.
23. Schwartz DR, Kardia SLR, Shedden KA, Kuick R, Michailidis G, Taylor JMG, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 2002;62: 4722-9.
24. Kalloger SE, Köbel M, Leung S, Mehl E, Gao D, Marcon KM, et al. Calculator for ovarian carcinoma subtype prediction. Mod Pathol 2011;24:512-21.
25. Kommoss S. Specialized pathology review in patients with ovarian cancer: results from a prospective study. Modern Pathol 2012; 25:281A.
26. Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 2010;134:907-22.
27. Sieh W, Köbel M, Longacre TA, Bowtell DD, Defazio A, Goodman MT, et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol 2013;14:853-62.
28. Kelemen LE, Goodman MT, McGuire V, Rossing MA, Webb PMon behalf of the Australian Cancer Study (Ovarian Cancer) , et al. Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the ovarian cancer association consortium. Cancer Epidemiol Biomarkers Prev 2010;19:1822-30.
29. Lee KR, Tavassoli FA, Prat J, Dietel M, Gersell DJ, Karseladze AI , et al. Surface epithelial stromal tumors. In: Tavassoli FA, Deville P, editors. World health organization classification of tumours: Pathology and genetics of tumours of the breast and female genital tract. Lyon: IARC Press; 2003. p. 117-46.
30. Goode EL, Chenevix-Trench G, Hartmann LC, Fridley BL, Kalli KR, Vierkant RA, et al. Assessment of hepatocyte growth factor in ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev 2011;20:1638-48.
31. Balogun N, Gentry-Maharaj A, Wozniak EL, Lim A, Ryan A, Ramus SJ, et al. Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking study. J Clin Epidemiol 2011;64:525-30.
32. Lo-Ciganic W-H, Zgibor JC, Bunker CH, Moysich KB, Edwards RP, Ness RB. Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, or acetaminophen and risk of ovarian cancer. Epidemiology 2012;23: 311-9.
33. Jones S, Wang T-L, Shih I-M, Mao T-L, Nakayama K, Roden R, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010;330:228-31.
34. Sim J, Wright CC. The kappa statistic in reliability studies: use, interpretation, and sample size requirements. Phys Ther 2005;85: 257-68.
35. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med 2012;9:e1001216.
36. Freedman OC, Dodge J, Shaw P, Oza AM, Bernadini M, Klachook S, et al. Diagnosis of epithelial ovarian carcinoma prior to neoadjuvant chemotherapy. Gynecol Oncol 2010;119:22-5.
37. McCluggage WG. My approach to and thoughts on the typing of ovarian carcinomas. J Clin Pathol 2008;61:152-63.
38. Soslow RA. Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol 2008;27:161-74.
39. Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol 2009;40:1213-23.
40. Soslow RA, Han G, Park KJ, Garg K, Olvera N, Spriggs DR, et al. Morphologic patterns associated withBRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol 2012;25:625-36.
41. Madore J, Ren F, Filali-Mouhim A, Sanchez L, Köbel M, Tonin PN, et al. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. J Pathol 2010; 220:392-400.